FORA Capital LLC Sells 19,191 Shares of IQVIA Holdings Inc. (NYSE:IQV)

FORA Capital LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 71.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 7,729 shares of the medical research company’s stock after selling 19,191 shares during the period. FORA Capital LLC’s holdings in IQVIA were worth $1,832,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. CreativeOne Wealth LLC raised its stake in IQVIA by 21.2% in the third quarter. CreativeOne Wealth LLC now owns 3,167 shares of the medical research company’s stock worth $750,000 after buying an additional 553 shares in the last quarter. Blueshift Asset Management LLC raised its position in shares of IQVIA by 53.2% in the 3rd quarter. Blueshift Asset Management LLC now owns 3,716 shares of the medical research company’s stock worth $881,000 after acquiring an additional 1,290 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in shares of IQVIA by 144.0% during the 3rd quarter. Glenmede Trust Co. NA now owns 306,511 shares of the medical research company’s stock worth $72,634,000 after purchasing an additional 180,890 shares during the last quarter. Townsquare Capital LLC boosted its position in IQVIA by 5.8% during the third quarter. Townsquare Capital LLC now owns 12,214 shares of the medical research company’s stock valued at $2,894,000 after purchasing an additional 666 shares in the last quarter. Finally, Baldwin Investment Management LLC raised its holdings in IQVIA by 8.6% in the third quarter. Baldwin Investment Management LLC now owns 3,548 shares of the medical research company’s stock worth $841,000 after purchasing an additional 280 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.1 %

Shares of NYSE:IQV opened at $201.44 on Thursday. The firm has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51. The business’s 50 day moving average price is $220.36 and its 200-day moving average price is $226.57. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Analyst Ratings Changes

A number of research firms have recently weighed in on IQV. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Morgan Stanley cut their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Barclays dropped their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.